Waterborne & Foodborne Diseases Questions

Typhoid, hepatitis A and E, cholera, dysentery (bacterial and amoebic), gastroenteritis from various viruses and bacteria, and — in specific outbreaks — leptospirosis after monsoon flooding. All spread through water or food contaminated by human faeces. Rates are highest in monsoon season, in areas with poor sanitation, and after floods.

Reputable brands from sealed bottles are generally safe. Local unbranded bottled water is variable — some is just tap water in a bottle. Look for BIS marking. Filtered water from a good home filter (UV + RO for most areas) is often more reliable long-term. Boiled water (rolling boil for 1-3 minutes) is a fallback anywhere. Ice, uncooked food washed in tap water, and street juices are common overlooked risks.

Typhoid causes a gradually rising fever over days, headache, abdominal discomfort, sometimes constipation or diarrhoea, and — classically — a rose-coloured rash on the trunk. Untreated, it can last weeks and cause serious complications (intestinal perforation, bleeding). Diagnosis is by blood culture. Treatment is with specific antibiotics; resistance to older antibiotics is common in India, so choice matters. Vaccine exists and is worth considering for travel or repeated exposure.

Cholera causes profuse watery diarrhoea and rapid dehydration — deadly if fluids aren't replaced quickly. Vibrio cholerae bacteria spread through contaminated water. India still sees cholera outbreaks, especially in poor sanitation areas and after natural disasters. Vaccination (oral cholera vaccine) is used in outbreak settings and for travellers to endemic areas. Prompt fluid replacement with ORS saves lives.

Boiling (rolling boil for 1-3 minutes) is the surest short-term method. Long-term: a good filter combining sediment filtration, activated carbon, RO (for hard/high-TDS water), and UV disinfection. Change filters as scheduled — an old filter is worse than no filter. Store treated water in clean, covered containers. Don't let children drink from open tanks or wells.

Getting infected and getting sick are two different things. Roughly one-third of the global population carries M. tuberculosis in latent form after some exposure, but only 5-10% ever develop active disease. Whether you progress from infection to active disease depends on multiple factors: immune status (HIV infection multiplies risk 20-30 times, diabetes doubles risk, aging weakens immunity), nutritional status (malnutrition dramatically increases risk), co-existing lung damage (smoking, silicosis, previous TB), genetic factors (specific HLA variants affect susceptibility), medications suppressing immunity (steroids, chemotherapy, TNF inhibitors), and the initial infecting dose. In India, the confluence of high HIV in some regions, high diabetes prevalence (over 100 million adults), household crowding, and undernutrition explains why India carries such a disproportionate share of the global TB burden despite decades of control efforts.

BCG (Bacillus Calmette-Guérin) vaccine has real but limited effectiveness. It reliably prevents severe childhood forms of TB. TB meningitis and disseminated (miliary) TB, with efficacy of 60-80%. It is far less effective at preventing adult pulmonary TB, with published efficacy ranging from 0% to 80% depending on the population studied, the variability itself is a major research puzzle, possibly related to prior exposure to environmental mycobacteria in different geographies. Despite this variability, India continues universal BCG vaccination at birth because the severe childhood TB prevention justifies it in a high-burden country; deaths from meningitis or miliary TB in unvaccinated Indian infants would be substantial. Improved TB vaccines are in active development globally (M72/AS01E is in phase 3 trials), but until one is approved, BCG remains standard for Indian newborns and provides genuine protection for the childhood forms that matter most in the neonatal period.

MDR-TB is TB resistant to at least isoniazid and rifampicin, the two most powerful first-line drugs. This resistance usually develops when patients receive inadequate treatment (wrong drugs, wrong doses, insufficient duration, or interruption), surviving bacteria multiply and become resistant. XDR-TB (extensively drug-resistant TB) is even more resistant, adding resistance to fluoroquinolones and injectable second-line drugs. India has among the largest number of MDR-TB cases globally. Treatment takes 9-24 months (vs 6 months for drug-sensitive TB), involves 4-7 medications simultaneously, causes more side effects, costs significantly more, and has lower cure rates (roughly 60-75% vs 85-95% for drug-sensitive TB). India's NTEP provides free MDR-TB diagnosis (GeneXpert MTB/RIF plus line probe assays) and treatment through dedicated DR-TB centres. Key patient rule: never stop TB treatment early even when feeling better, never skip doses, never take TB medications from unknown sources, creating MDR-TB harms both the patient and the community for decades.

The NS1 antigen appears in blood as early as day 1 of fever and stays detectable through roughly day 5-7. That is the window where NS1 is most sensitive. If you have fever with any classic dengue features, sudden high fever, severe body aches (especially behind the eyes), headache, nausea, or a rash, and you are anywhere in India during monsoon or early post-monsoon (June-November), ask your doctor about NS1 on the same day fever starts. Waiting past day 5 makes NS1 progressively less sensitive; after day 7, IgM antibody test becomes more useful. Testing on day 0-1 of fever occasionally gives false negatives because viral load has not yet peaked, a repeat test 24-48 hours later resolves this.

Three different things at three different time points. NS1 detects a viral protein made by the dengue virus itself, positive from day 1-7, catches active infection early. IgM antibody appears from day 5-7 onwards and stays positive for 2-3 months, catches recent infection, useful when NS1 window has passed. IgG antibody appears from day 7-14 and stays positive for years, indicates past infection or immunity, not useful for diagnosing current fever alone. In practice, doctors often order NS1 + IgM together in the first week of fever, since together they cover the whole infection window. IgG is only useful in specific situations like distinguishing primary vs secondary dengue (secondary infection has higher risk of severe dengue).

A positive NS1 confirms dengue and shifts the focus to monitoring for complications, since there is no antiviral treatment. Immediate steps your doctor will typically arrange: (a) baseline CBC to check platelet count and hematocrit; (b) monitoring platelet count daily during the critical phase (day 3-7 of fever), platelets can drop rapidly; (c) hydration guidance, oral or IV fluids as needed, particularly during the fever-defervescence phase which is when severe dengue often develops; (d) avoiding aspirin, ibuprofen, and other NSAIDs because they raise bleeding risk in dengue, paracetamol (acetaminophen) is the only safe antipyretic; (e) hospitalisation if warning signs appear (severe abdominal pain, persistent vomiting, bleeding from gums or nose, lethargy, cold extremities). The critical period is when fever breaks around day 4-6, that is the window to watch most carefully, not the fever itself.

A negative NS1 does not rule out dengue, especially in the first 24-48 hours of fever (viral load may not yet be at detectable levels) or after day 5-7 (NS1 window has closed). Practical next steps: (a) if you tested on day 1-2 of fever, repeat NS1 after 24-48 hours, sensitivity improves as viral load rises; (b) if fever has been going 5+ days, ask for IgM antibody test which becomes positive around day 5-7; (c) simultaneously rule out other Indian monsoon fevers with overlapping symptoms, malaria (blood smear + RDT), typhoid (Widal or blood culture), leptospirosis, chikungunya, and viral hepatitis all present similarly. Do not assume 'just viral fever' if fever continues past 48-72 hours without a diagnosis, return to your doctor for expanded workup rather than waiting it out at home.

NS1 (nonstructural protein 1) is a glycoprotein made by the dengue virus during its replication inside human cells. It is secreted into the bloodstream in large quantities from day 1 of infection, reaching detectable levels typically within 24 hours of fever onset and remaining detectable through roughly day 5-7. This early appearance makes NS1 uniquely useful because it fills the diagnostic gap before your body has produced detectable antibodies (IgM appears around day 5-7, IgG around day 7-14). NS1 is highly specific to flaviviruses (dengue, Zika, yellow fever), so a positive result in an Indian patient with fever during dengue season is almost certainly dengue, since Zika and yellow fever are rare here. Testing methods: ELISA is the lab standard (highest sensitivity); rapid diagnostic test (RDT) kits give point-of-care results in 15-30 minutes with slightly lower sensitivity.

Both detect the same NS1 antigen but differ in sensitivity, turnaround, and cost. NS1 ELISA (enzyme-linked immunosorbent assay): performed in a diagnostic laboratory, sensitivity typically 85-95%, results in 4-24 hours depending on lab batching, moderate cost. This is the standard reference test. NS1 rapid diagnostic test (RDT) kits: performed at point-of-care (clinic, small lab, some pharmacies), sensitivity typically 70-85%, results in 15-30 minutes, lower cost. RDTs are useful when time matters and lab access is limited, a positive RDT is highly reliable, but a negative RDT should ideally be confirmed with ELISA if clinical suspicion remains high. In India during dengue outbreaks, RDT-first-then-ELISA-if-negative is a common approach, particularly outside tier-1 cities where lab turnaround can slow the diagnosis.

In principle yes. NS1 tests can show cross-reactivity with other flaviviruses because these viruses share protein structures. In practice for Indian patients this is rarely a clinical issue: Zika virus is uncommon in India (small outbreaks reported), yellow fever is not endemic in India (a few imported cases), and Japanese encephalitis (JE) does exist but the clinical presentation differs enough that dengue vs JE is usually distinguishable clinically. For most Indian patients with fever and a positive NS1 test during dengue season, the result reliably indicates dengue. Where confusion can arise: recent yellow fever vaccination (given for international travel) or recent JE vaccination can occasionally cause transient antibody cross-reactivity, though this affects IgM tests more than NS1 antigen tests. If cross-reactivity is a genuine concern (post-travel, unusual clinical picture), confirmatory testing with dengue-specific PCR resolves it.

A negative NS1 test does not rule out dengue, it needs interpretation in context of when in the illness you tested. Common reasons for a false-negative NS1: (a) tested too early (first 24 hours of fever, viral load still rising below detection threshold); (b) tested too late (after day 5-7, NS1 has cleared from blood but antibodies are now present); (c) secondary dengue infection in someone previously infected with a different serotype, pre-existing IgG antibodies bind NS1 and reduce its detectability; (d) infection with certain P. vivax-like less common serotypes with lower NS1 production. Next steps for a symptomatic patient with negative NS1: repeat NS1 in 24-48 hours if still within day 1-5 window, or add IgM antibody test if past day 5, or PCR testing at a tertiary centre for definitive diagnosis. Do not accept 'ruled out dengue' from a single NS1 without considering timing, one test does not close the case if symptoms strongly suggest dengue.

The three anchor diagnoses in most cases: Hyperthermia related to underlying infection or inflammatory process (as evidenced by elevated body temperature above 38°C, warm skin, tachycardia); Deficient Fluid Volume or Risk for Deficient Fluid Volume related to excessive fluid loss from vomiting and insensible loss from fever (evidenced by decreased urine output, dry mucous membranes, tachycardia, hypotension); and Nausea related to gastrointestinal irritation, drug side effects, or central causes (evidenced by patient report and observed retching). Secondary diagnoses to consider based on presentation: Risk for Electrolyte Imbalance, Acute Pain (headache or abdominal), Imbalanced Nutrition Less than Body Requirements if vomiting is protracted, and Risk for Infection Transmission when the underlying cause is a communicable pathogen. Priority ordering follows Maslow, fluid balance first, then temperature, then comfort.

At minimum every 4-6 hours during the acute phase: temperature (route consistent, oral, axillary, or tympanic; note the route), heart rate, blood pressure (including orthostatic if the patient is ambulant), respiratory rate, oxygen saturation, level of consciousness, and pain score. Fluid balance: strict intake and output charting, urine specific gravity or colour observation, weight if possible daily at the same time. Vomiting characterisation: frequency, volume, colour and content (bilious, coffee-ground, undigested food, blood), and relation to food or medication. Assess mucous membranes, skin turgor, and capillary refill each shift for hydration status. In endemic Indian settings, note any petechiae, rash, or bleeding, early signs of severe dengue that shift the care plan significantly.

Establish IV access early, deteriorating patients can lose the option to hydrate orally quickly. Initiate rehydration per protocol (oral rehydration solution if tolerated; IV normal saline or Ringer's lactate if vomiting persists or dehydration is significant), correcting electrolyte deficits based on baseline labs. Administer prescribed antipyretic (paracetamol is first-line; avoid NSAIDs if dengue is on the differential due to bleeding risk) and prescribed antiemetic (ondansetron is common first-line for adults; metoclopramide alternatives). Cooling measures: tepid sponging if temperature is over 39°C, adequate exposure, ambient temperature control. Send off diagnostic samples early. CBC, electrolytes, urea/creatinine, urine routine, and pathogen-specific tests based on epidemiology (dengue NS1, malaria smear, typhoid Widal or blood culture, stool if diarrhoea present). Document baseline for evaluation.

Objective indicators of successful intervention within 24-48 hours: temperature trending down toward 37.5°C or lower without persistent antipyretic dependence; vomiting frequency reduced by at least 50%, patient tolerating small oral fluid volumes; urine output restored to at least 0.5 mL/kg/hour with clearing urine colour; heart rate and blood pressure normalising toward baseline; improving level of consciousness and patient-reported comfort. Red flags requiring escalation to the treating physician: persistent fever above 39°C beyond 48 hours of appropriate antipyretic use, worsening tachycardia despite fluid replacement, oliguria, altered mental status, new bleeding manifestations (particularly relevant in the Indian dengue season), rising creatinine, or persistent inability to tolerate oral intake. The care plan is not a static document, nursing diagnoses should be re-prioritised as the aetiology clarifies from diagnostic workup.

Neither. Malaria is caused by a single-celled parasite called Plasmodium, technically a protozoan, one of the oldest kinds of life on earth. Five species infect humans: P. falciparum (the most dangerous, common in Africa and parts of India's North-East and eastern states), P. vivax (the most widespread in India, causes relapsing infections), P. ovale, P. malariae, and P. knowlesi (rare, mainly South-East Asian forest exposure). Because it is a parasite and not a bacterium or virus, malaria does not respond to antibiotics or antiviral medicines. It needs specific antimalarial drugs, chloroquine, artemisinin-based combinations, or primaquine, depending on the species and drug-resistance pattern in the region.

The bite injects fewer than a hundred parasite sporozoites into your bloodstream, a tiny number, but they head straight for the liver within an hour. Inside a liver cell, each sporozoite multiplies silently over 7-30 days into tens of thousands of new parasites (merozoites). When the liver cell bursts, those merozoites flood into your bloodstream and start invading red blood cells. Each infected red cell then bursts every 48-72 hours, releasing more parasites, and this is when you first feel sick. So the mosquito bite is small, but the liver stage is a hidden multiplier that turns a handful of parasites into millions before symptoms even begin.

Because the parasite's blood-stage cycle is synchronised. All the infected red blood cells burst at roughly the same time, every 48 hours for P. vivax and P. ovale (tertian fever), 48 hours for P. falciparum (though often less regular), and 72 hours for P. malariae (quartan fever). Each mass rupture releases parasites plus toxic parasite waste products into the bloodstream, which triggers the immune system to spike fever, chills, and shivering, the classic malaria paroxysm. Between paroxysms, the parasite is quietly invading fresh red blood cells and you feel relatively normal. This cyclical pattern is so distinctive that a fever every other day in someone who has been in an endemic area should trigger a malaria test even before other symptoms develop.

Both P. falciparum and P. vivax are prevalent in India but they behave differently. P. falciparum is more common in Odisha, Chhattisgarh, Jharkhand, and the North-East and causes almost all severe and fatal malaria, cerebral malaria, kidney failure, ARDS, severe anaemia. It progresses fast and can kill within days if untreated. P. vivax is more widespread across the country and causes fewer deaths but has two features that matter: relapses can occur months to years after the original infection because dormant liver-stage parasites (hypnozoites) can reactivate, and chronic P. vivax weakens people over time. Any fever after being in a mosquito-endemic area should be tested regardless of which species is more common there, waiting to see if it is just viral fever can be dangerous with P. falciparum.

Latent TB means the M. tuberculosis bacteria are in your body but contained by your immune system inside granulomas, you have no symptoms, are not infectious, and cannot spread the disease. Chest X-ray is usually normal; TB is detected only through Mantoux test or IGRA blood test. Active TB means the bacteria have broken out of containment and are multiplying, causing symptoms (persistent cough, weight loss, night sweats, low-grade fever) and making you infectious to others. Roughly 5-10% of people with latent TB will develop active TB at some point in their lifetime, with the risk highest in the first 2 years after exposure and in anyone whose immune system weakens (HIV, diabetes, steroids, TNF inhibitors, aging). Whether latent TB needs treatment depends on individual risk. WHO recommends preventive treatment for household contacts of active TB cases, HIV-positive people, people starting immunosuppressive drugs, and healthcare workers with recent conversion. India's NTEP is expanding preventive TB treatment access, particularly for household contacts.

Ask for a peripheral blood smear as your primary test, thick smear for detection, thin smear for species identification. A rapid diagnostic test (RDT) is a reasonable add-on, especially if you are in a smaller clinic or evening hours when a microscopist may not be available; RDT gives a result in 15-20 minutes. If both are negative but fever and symptoms persist for another 24-48 hours, a repeat smear at a good centre or a PCR test at a tertiary hospital is the next step. Do not rely on RDT alone if your clinical picture is convincing, low-parasitemia infections and non-falciparum species (P. vivax, P. ovale) can be missed by rapid tests.

In government hospitals, both RDT and blood smear are typically free or nominal. In private labs, RDT and blood smear together are usually affordable and results come back the same day. RDT within 20-30 minutes, smear within 2-4 hours if the lab has a technician on shift. PCR is only available at larger hospitals and reference laboratories; it is significantly more expensive and takes 24-72 hours depending on the batch schedule. For anyone with fever in an endemic area, testing should not be delayed by cost, a delayed diagnosis in P. falciparum malaria can escalate to cerebral malaria within days.

A negative RDT does not rule out malaria, especially in the first 24-48 hours of illness or in P. vivax infection where parasite levels can be low. Next steps: (a) request a thick and thin blood smear read by an experienced microscopist, this is more sensitive than an RDT and identifies the species; (b) if smear is also negative but fever continues past 48 hours, repeat the smear, parasitemia rises with each fever cycle and can become detectable; (c) discuss PCR testing at a tertiary centre if smears remain negative but symptoms are strongly suggestive; (d) in parallel, work up other causes of fever in India, dengue, typhoid, chikungunya, leptospirosis, urinary infection, since these can co-exist or mimic malaria.

Very urgent, especially if you have travelled to sub-Saharan Africa, the Indian North-East, Odisha, Chhattisgarh, or parts of South-East Asia where P. falciparum is common. Get tested the same day. P. falciparum malaria can progress to severe disease within 24-72 hours of first symptoms, cerebral malaria, kidney failure, severe anaemia, ARDS. Tell the doctor exactly where you travelled, when, and whether you took prophylaxis. If travel was to a P. vivax or P. ovale region, symptoms can appear weeks to months after return because these species can lie dormant in the liver, any unexplained fever within a year of travel to an endemic zone warrants a malaria test, not just antibiotics for a presumed viral illness.

Modern malaria RDTs have sensitivity of roughly 90-95% for detecting Plasmodium falciparum at typical fever-onset parasite levels, meaning they catch most cases but can miss around 5-10%. Sensitivity for P. vivax is lower, around 80-90%, because the antigens vary more across strains. Sensitivity drops significantly when parasite counts are very low (early in the illness or in asymptomatic carriers). Blood smear microscopy remains the gold standard, with sensitivity approaching 95% in expert hands and the ability to identify species and quantify parasite load. In practice, RDT is the fast first test almost anywhere in India; blood smear confirms the diagnosis and guides treatment intensity. A negative RDT with persistent malaria-suggestive symptoms should always trigger a follow-up smear rather than being taken as definitive.

Malaria RDT kits are available in India but not typically sold for home use, they are meant for clinical or field-worker settings and are usually sold to hospitals, primary health centres, NGOs, and pharmacies for point-of-care testing rather than direct-to-consumer. Even where available at retail pharmacies, home use is not recommended because: interpreting a faint test line correctly needs practice, a negative result does not rule out early-stage malaria and needs follow-up, and any positive result immediately needs a doctor visit for treatment (antimalarials are prescription-only). Practical alternative: same-day RDT plus blood smear at a diagnostic lab or general practitioner clinic is inexpensive and available in most Indian cities. Do not delay treatment while trying to diagnose at home if you have symptoms consistent with malaria after mosquito exposure.

RDTs use protein-based antibodies that degrade at high temperatures, accuracy drops meaningfully when kits are stored above 30°C for extended periods, which is a real issue in Indian summers and in rural clinics without air conditioning. Storage above 40°C can produce false negatives even for kits well within their expiry date. Practical implications: kits held in unrefrigerated pharmacy shelves during peak summer months (April-June) may perform worse than the manufacturer's stated sensitivity; kits transported without cold-chain protection in field settings often lose reliability. This is why WHO recommends RDT lot testing before deployment in endemic areas. For patients: if an RDT result seems inconsistent with your clinical picture, ask for a blood smear rather than trusting the RDT alone, the smear does not have storage-related accuracy issues.

A positive RDT confirms malaria and shifts focus immediately to two things: (a) determining severity, a doctor evaluates whether it is uncomplicated malaria (treatable at home with oral antimalarials) or severe malaria (needs hospitalisation and IV artesunate). Severe malaria indicators include altered consciousness, seizures, jaundice, dark urine, breathing difficulty, or extreme weakness. (b) identifying species, this determines the drug regimen. For P. falciparum in India, artemisinin combination therapy (ACT) is first-line; for P. vivax, chloroquine plus primaquine (primaquine treats the dormant liver stage to prevent relapse). The doctor will also order a follow-up blood smear to quantify parasite load and check response to treatment at day 3. Do not self-treat with over-the-counter antimalarials on a positive RDT, the wrong drug or dose can drive resistance and worsen outcomes.

A raised CRP usually means more inflammation in the body — in COVID-19, it often signals more severe lung involvement. CRP (C-reactive protein) is a protein your liver releases whenever there's active inflammation from infection, injury or immune activity. In a healthy adult it stays below 5–10 mg/L. In mild COVID, CRP typically stays under 40 mg/L. Values above 40–100 mg/L suggest moderate disease with likely pneumonia, and levels above 100 mg/L are strongly linked to severe COVID pneumonia, higher oxygen needs and ICU admission. A single CRP reading has limits, but rising CRP over 24–48 hours is one of the strongest early warning signs of worsening COVID and often triggers the decision to admit, escalate oxygen or start anti-inflammatory drugs like dexamethasone.

The Widal test has significant limitations and is now considered unreliable when used alone for typhoid diagnosis. False positives are common — endemic areas have background elevated titers from past exposure or vaccination, and cross-reaction occurs with other Salmonella species, malaria, dengue, and viral infections. False negatives happen in the first week of illness (before antibody rise), in immunocompromised patients, and with early antibiotic treatment. Baseline elevated titers are a real problem: in endemic Indian regions, 5-25% of asymptomatic healthy people have Widal titers of 1:80 or higher just from past exposure — so a single elevated titer is meaningless. Proper interpretation requires paired samples 7-14 days apart showing a 4-fold rise — rarely done in practice. The low cost of Widal makes it commonly used but leads to overdiagnosis and unnecessary antibiotics. Modern gold standard: BLOOD CULTURE — collect 3-5 ml blood in specialised bottles before antibiotics; positive in 70-90% of cases in the first week, declining thereafter; identifies exact organism and antibiotic sensitivity. Better alternatives: blood culture always preferred; bone marrow culture (over 90% sensitivity even after antibiotics); Typhidot IgM (more specific than Widal, positive from day 3-5); Enterocheck WB rapid test; IDL Tubex immunoassay. WHO recommends against Widal test where blood culture is available.

Diagnostic approach: (1) Blood culture in first week (best sensitivity 70-90%) — do BEFORE any antibiotics; (2) If already on antibiotics or blood culture negative but strong suspicion — bone marrow culture (>90% sensitivity even after antibiotics); (3) Typhidot IgM as adjunct (positive day 3-5); (4) Widal only if better tests unavailable — interpret with caution using paired samples showing 4-fold rise. Clinical clues: gradual stepwise fever rise over week, relative bradycardia (pulse slower than expected for fever), abdominal pain, constipation initially then diarrhoea (‘pea-soup’ stools classic), rose spots (small blanching macules on trunk — often missed), splenomegaly, hepatomegaly. Treatment (based on culture sensitivity): (1) UNCOMPLICATED CASES — Azithromycin 500mg once daily for 7-10 days (first-line India due to widespread fluoroquinolone resistance); OR Cefixime 200mg BD for 10-14 days; (2) COMPLICATED/SEVERE — Ceftriaxone 2g IV once daily 10-14 days; ICU admission if severe; (3) MDR/XDR TYPHOID (increasing in India, especially Sindh-linked strains) — meropenem or azithromycin per sensitivity; specialist care needed; (4) DEFERVESCENCE takes 3-7 days on appropriate antibiotic; incomplete response = check compliance, sensitivity, complications; (5) SUPPORTIVE CARE — hydration, nutrition, paracetamol for fever, monitor for complications (intestinal perforation, bleeding, myocarditis, hepatitis). Complications: 10-15% untreated cases develop severe complications; intestinal perforation 1-3% (surgical emergency).

Typhoid remains endemic across India with 400,000+ cases annually. Prevention: (1) VACCINATION — Multiple vaccines available: (a) Typbar TCV (Bharat Biotech) — typhoid conjugate vaccine; single dose from 6 months; long-lasting protection; ~85% effective; WHO-prequalified; (b) Typhim Vi / Typherix — polysaccharide vaccine; single dose age 2+; needs booster every 3 years; ~55-72% effective; (c) Vivotif (oral live typhoid) — 4 capsules alternate days; less used in India. RECOMMENDED FOR: children 9 months+ under UIP (recently added), travellers to endemic areas, food handlers, laboratory workers, healthcare workers, household contacts of chronic carriers, high-risk residents. (2) FOOD & WATER HYGIENE — (a) Drink only boiled/filtered water (RO + UV) or sealed bottled water from trusted brand (check seal, expiry); (b) Avoid ice from unknown source; (c) Avoid street food, especially cut fruits, chutneys, sauces sitting out; (d) Eat only thoroughly cooked hot food; (e) Wash hands with soap before eating, after toilet; (f) Peel your own fruits; (g) Avoid raw vegetables/salads at questionable restaurants. (3) SANITATION — safe waste disposal, treated water supply, hand hygiene education. (4) CARRIER DETECTION — some patients become chronic carriers (Salmonella typhi in gallbladder); stool culture screening for food handlers, healthcare workers. (5) OUTBREAK RESPONSE — public health notification, contact tracing, source investigation, mass vaccination if indicated. India needs multipronged approach: universal typhoid conjugate vaccination in childhood + hygiene infrastructure + antimicrobial stewardship to prevent XDR typhoid emergence.

Test selection depends on timing of illness: (1) DAY 1-5 of fever (early illness) — NS1 ANTIGEN test is BEST; detects dengue viral protein in blood before antibodies form; sensitivity 70-90% days 1-3, drops after day 5; sample = single blood draw; (2) DAY 5+ of fever — IgM antibody test becomes positive; detects immune response; specific for recent infection; (3) IgG antibody — high in secondary dengue (previous dengue + new infection) — indicates increased severity risk; useful in outbreak epidemiology; (4) RT-PCR (viral RNA) — most accurate early (day 1-5) but expensive; typically reserved for confirmed severe cases, atypical presentations, research; not routine; (5) NS1 + IgM combination panel — covers both early and later phases; commonly ordered when timing unclear. ADDITIONAL essential tests during dengue: (1) CBC with platelet count — repeat every 12-24 hours; watch for drop below 100,000 (warning), below 20,000 (bleeding risk); (2) Hematocrit — rising Hct indicates plasma leakage (severe dengue warning); (3) LFT — elevated in most dengue; hepatitis component; (4) Coagulation profile if bleeding suspected. Modern dengue management is guided by daily monitoring, not just diagnostic test at admission.

Dengue phases and warning signs: FEBRILE PHASE (Days 1-3): sudden high fever 39-40°C, severe body ache, headache, retro-orbital pain, joint pain (‘breakbone fever’), nausea, vomiting, rash. Most patients recover from here. CRITICAL PHASE (Days 3-6): as fever DECREASES (defervescence), 5-10% develop severe complications — PLASMA LEAKAGE. Warning signs of severe dengue: (1) Persistent vomiting (>3 episodes in hour); (2) Severe abdominal pain (constant, not just cramping); (3) Bleeding — nose, gums, bruising, blood in vomit/stool/urine, menstrual excess; (4) Restlessness or lethargy; (5) Cold clammy extremities; (6) Rapid weak pulse, drop in BP; (7) Difficulty breathing; (8) Marked drop in platelet count (<50,000); (9) Rising hematocrit >20%; (10) Reduced urine output. RECOVERY PHASE (Days 6-10): fluid reabsorbs, rash may recur, gradual improvement. When to seek emergency care immediately: any of the warning signs above; especially if fever suddenly drops but patient appears WORSE (not better) — critical phase warning; sudden severe abdominal pain; bleeding from any site; altered mental state; dizziness on standing. India-specific: dengue outbreaks worst in monsoon (July-October); Bangalore, Delhi, Kolkata, Chennai, Ahmedabad among high-burden cities; mosquito breeding in stored water containers (bucket, cooler, flower pot, tyre); Aedes mosquito bites during daytime especially early morning + late afternoon; use repellent (DEET 20-30% or picaridin), full-sleeve clothing, mosquito nets.

Dengue treatment is supportive — NO specific antiviral: (1) FLUIDS are the cornerstone — oral in mild cases (WHO ORS, coconut water, dal ka pani, buttermilk, fresh fruit juice), IV in severe cases (crystalloids like Ringer’s lactate); careful fluid balance critical — under-hydration + shock danger, over-hydration + pulmonary oedema danger; (2) PARACETAMOL for fever (500-1000mg every 4-6 hours, max 4g/day); AVOID aspirin, ibuprofen, other NSAIDs (increase bleeding risk); AVOID intramuscular injections (haematoma risk); (3) MONITORING — daily CBC (platelet + hematocrit), symptom assessment, fluid intake/output balance, vital signs; frequency depends on severity; (4) HOSPITALISATION indicated for: any warning sign, high-risk patients (pregnancy, elderly, comorbidities), inability to maintain oral hydration, platelet count <50,000. PLATELET TRANSFUSION — commonly over-used; guidelines: (1) Platelet transfusion NOT indicated for count alone (up to 20,000-30,000 without bleeding — no transfusion needed); (2) Indicated for: active bleeding + thrombocytopenia; platelet count <10,000 with high-risk factors; before invasive procedures; (3) Random donor platelets are less expensive but need multiple units to raise count meaningfully; single donor platelets (SDP) are more expensive; (4) Papaya leaf extract — no strong evidence but widely used; likely safe; do NOT replace medical care. FLUID MANAGEMENT: crystalloids first-line; colloids if inadequate response; blood transfusion if bleeding-related anaemia. RECOVERY: most uncomplicated cases recover 7-10 days; fatigue can persist weeks. Post-dengue: rare complications include prolonged fatigue, joint pain, hair loss; secondary dengue increases severity risk — dengue vaccination (Dengvaxia, QDenga) only for previously infected individuals in specific contexts.

NS1 (non-structural protein 1) is a protein produced by the dengue virus itself — not by the patient's immune system. Because the virus starts replicating immediately after infection, NS1 floods the bloodstream within hours and is detectable in blood from day 1 of fever, sometimes even a few hours before symptoms start. This is the key advantage over antibody tests: antibody-based tests (IgM/IgG) detect the body's response to dengue, which takes 4–7 days to build up to detectable levels. In the first 5 days of illness — when fever is high, the patient is most unwell, and the clinical picture is unclear — the NS1 test is the primary diagnostic tool. After day 5, NS1 levels fall as the immune system clears the protein, and antibody tests (IgM ELISA or rapid combo cards) take over as the more reliable option. All four dengue serotypes (DENV-1 to DENV-4) produce NS1, so the test works regardless of which serotype is circulating in the current outbreak.

A positive NS1 test means the dengue virus is actively replicating in the blood right now — this is a confirmed dengue infection, not a past exposure or a false alarm from vaccination. The next steps depend on clinical severity. For most patients with uncomplicated dengue (fever + body aches + rash, no warning signs), a positive NS1 leads to: admission or close home monitoring with daily or twice-daily platelet and haematocrit checks, oral hydration with 2–3 litres of fluid per day (ORS, coconut water, water), paracetamol for fever (never aspirin or ibuprofen — these increase bleeding risk by inhibiting platelets), and strict bed rest. Warning signs that require immediate hospitalisation regardless of test result: severe abdominal pain, persistent vomiting, bleeding from gums or nose, blood in urine or stools, sudden drop in platelet count below 20,000, or altered consciousness. A single positive NS1 is sufficient to start treatment — no second test is needed to confirm. However, because NS1 cross-reacts with other flaviviruses (Zika, West Nile, Japanese encephalitis), a positive result in a non-dengue-endemic area or during a known Zika outbreak should be interpreted carefully alongside clinical context.

Yes — a negative NS1 does not rule out dengue, and this is the most important limitation to understand. False negatives happen in two situations: (1) Testing too late — NS1 is most detectable in days 1–5 of fever; by day 6–7 the immune system starts clearing it and levels fall below the test's detection threshold even though the patient is still sick. If you test on day 6 or later and the NS1 is negative, a dengue IgM antibody test should be added. (2) Secondary dengue infection — people who have had dengue before (a different serotype) tend to produce a faster and stronger antibody response in the second infection, which binds and clears NS1 quickly, lowering detectable levels and causing NS1-negative results even in early illness. In a secondary infection, dengue IgG is typically elevated from the start. Rapid combination cards (NS1 + IgM + IgG on one strip) are more accurate than NS1 alone in secondary infections because they pick up the early IgG signal that primary infection cards miss. If clinical suspicion is high — high-grade fever in a dengue-endemic area during outbreak season, with severe myalgia, retro-orbital pain and rash — treat as probable dengue and repeat testing the next day even if the first result is negative.

There are three main dengue test types, each useful at a different point in the illness. NS1 antigen test: best in days 1–5; detects active viral replication; a positive is diagnostic; available as rapid card test (result in 15–20 minutes) or ELISA (more quantitative, used in labs). IgM antibody test: detects the body's primary immune response; turns positive from about day 4–5 and peaks at 2–3 weeks; best for confirming dengue in the second week of illness or if the patient presents late; a positive IgM alongside symptoms in an endemic area is clinically diagnostic. IgG antibody test: detects past or secondary infection; already high at illness onset in secondary dengue; useful for epidemiological studies and to identify secondary infections. In practice, most hospitals and clinics now use combination rapid cards (NS1 + IgM + IgG) from a single finger-prick sample — these cover both early and late presentations in one test. Blood culture is not used for dengue (the virus cannot be easily cultured in routine labs). PCR (RT-PCR) is the most accurate test but expensive, slow (24–48 hours), and reserved for severe or unusual cases, research, or outbreak investigation where serotype identification matters.

The top three NANDA-approved diagnoses for a febrile patient are Hyperthermia, Risk for Deficient Fluid Volume, and Impaired Comfort. Hyperthermia (body temperature above 38.3°C / 101°F) is typically the primary diagnosis because it is the defining clinical problem and drives most interventions — antipyretic administration, tepid sponging, light clothing and bedding, and environmental cooling. Risk for Deficient Fluid Volume is second-priority because fever accelerates insensible fluid loss through sweating and increased respiratory rate; without aggressive oral or IV rehydration the patient can dehydrate rapidly. Impaired Comfort addresses the associated headache, myalgia, chills and restlessness. Secondary diagnoses to consider include Risk for Febrile Seizure (in children under 5 or with a prior seizure history) and Deficient Knowledge if the patient and family cannot yet identify warning signs. In GNM and BSc Nursing examinations, always state the diagnosis in NANDA format: problem + related factor + as evidenced by (PES format).

Nursing interventions for the Hyperthermia diagnosis combine pharmacological and non-pharmacological strategies. Start by monitoring core temperature every 2–4 hours (or every 1 hour during a febrile spike) using the same route each time for consistency. Administer antipyretics — paracetamol 650 mg or ibuprofen — as prescribed, documenting time, dose, route and effect. Non-pharmacologically: apply tepid water sponging (30°C water — not cold, which causes shivering and raises core temperature), provide lightweight cotton clothing, open windows or use a fan, and keep the room temperature at 22–24°C. Encourage oral fluids 2–3 L per day unless contraindicated; if the patient cannot tolerate oral fluids, assist with IV line preparation as ordered. Remove excess bedding. Monitor for shaking chills, which precede a temperature spike — apply a light blanket during rigors to prevent energy expenditure from violent shivering. Document all temperatures and interventions in the nursing notes and report a temperature above 39.5°C or failure to respond to antipyretics within 1 hour to the physician.

Evaluation criteria are directly tied to the expected outcomes set during planning. For Hyperthermia the expected outcome is: body temperature returns to and remains within 36–37.5°C within 2–4 hours of intervention. You evaluate this by charting serial temperatures — if the downward trend is consistent and the patient reports less discomfort, the intervention is working; if temperature remains above 38.3°C after two antipyretic doses plus physical cooling, escalate to the physician. For Fluid Volume the expected outcome is: urine output ≥ 30 mL/hour, moist mucous membranes, stable pulse and blood pressure. Check skin turgor and urine colour as quick bedside indicators. For Impaired Comfort the expected outcome is: patient reports pain/discomfort ≤ 3 on a 0–10 scale. If any outcome is not met within the timeframe, the care plan must be revised — reassess the underlying cause of fever (is there a new focus of infection?), review medication efficacy, and consider ordering additional diagnostic tests such as blood culture or CBC. For nursing examination answers, explicitly state the evaluation statement: 'Goal met / partially met / not met' with supporting evidence.

Patient and family education is a core component of the NCP and is frequently examined in GNM and BSc Nursing papers. Key teaching points: (1) How to measure temperature correctly — axillary, oral or tympanic; when to use each site; and what number warrants calling a doctor (>38.5°C in adults, >38°C in infants under 3 months). (2) Antipyretic use: correct dose of paracetamol for the patient's weight, do not exceed 4 g/day in adults, do not give aspirin to children under 12 due to Reye's syndrome risk. (3) Hydration: drink at least 2–3 litres of water, coconut water, oral rehydration solution or clear soup daily; avoid alcohol and caffeinated drinks which increase fluid loss. (4) Warning signs requiring immediate return to hospital: fever above 40°C, febrile convulsion, stiff neck, severe headache, persistent vomiting, or rash — these may indicate meningitis, encephalitis, or severe dengue, not simple pyrexia. (5) Complete the antibiotic course if one was prescribed — stopping early causes resistance and relapse. Document that education was given and the patient/family demonstrated understanding (teach-back method).

H3N2 is a subtype of influenza A virus circulating globally. It emerged in 1968 as a pandemic strain (Hong Kong flu) and has continued as a seasonal flu virus with periodic strain updates. Compared to other flu types: H3N2 tends to cause more severe illness than H1N1 (swine flu) in elderly and vulnerable populations, with higher hospitalisation and mortality rates; H1N1 more affects younger adults and children; influenza B typically causes milder illness; H3N2 evolves faster (antigenic drift), so vaccines need annual updates and effectiveness varies year-to-year (typically 30-60%). India-specific patterns: the Feb-April 2023 H3N2 outbreak caused significant illness across Karnataka, Maharashtra, Tamil Nadu, and Delhi; cases usually surge in monsoon (July-Sept) and post-monsoon (Oct-Nov); the 2023 outbreak had unusually severe respiratory symptoms with prolonged cough (3-4 weeks); co-circulation with COVID, adenovirus, and RSV made clinical differentiation difficult without testing. Typical symptoms: sudden fever (often 102-104°F), dry cough (can be severe or persistent), sore throat, body ache, extreme fatigue, headache, chills. Acute symptoms last 3-7 days; cough may persist 2-4 weeks.

Diagnosis: most cases are managed clinically without testing — symptoms plus community outbreak context are sufficient. When testing is needed: RT-PCR for influenza A/B is most accurate and identifies specific subtype, typically 4-12 hour result. Rapid Influenza Diagnostic Tests (RIDT) give results in 15-30 minutes with lower sensitivity (60-70%) than RT-PCR but useful in clinical decision-making. Multiplex respiratory panels (flu A/B + COVID + RSV + adenovirus) are useful when differentiating is important. Treatment: OSELTAMIVIR (Tamiflu) 75 mg twice daily for 5 days in adults (weight-based child dose) is MOST EFFECTIVE when started within 48 hours of symptom onset; reduces illness duration by 1-2 days, hospitalisation risk by 40-50%, and secondary complications — especially valuable for high-risk patients (elderly, pregnant, chronic disease, immunocompromised). ZANAMIVIR (inhaled) is an alternative — not preferred in asthma/COPD. Baloxavir is newer, single-dose, limited availability. Symptomatic: paracetamol for fever (avoid aspirin in children — Reye syndrome risk); adequate fluids, rest; avoid dry cough suppressants unless disrupting sleep. Antibiotics have NO role for viral flu unless bacterial complication (pneumonia, sinusitis, otitis) develops — over-prescription is a significant issue. Hospitalization needed if: severe respiratory distress, hypoxia (SpO2 under 94%), altered mental state, dehydration, or high-risk patient with severe symptoms.